Kailera says obesity pill succeeds in late-stage trial in China

Phase 3positivePositive

AI Analysis

Summary

Kailera's obesity pill achieved approximately 10% weight loss over 10 months in a late-stage trial in China. The positive efficacy finding was tempered by significant gastrointestinal side effects that raised concerns among analysts.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Achieved approximately 10% weight loss over 10 months; high rates of gastrointestinal side effects observed

Importance:7/10

Sentiment:

0.40

obesityweight losslate-stage trialChinagastrointestinal side effects

Related Companies

$KLRA

Read the original article

Published by BioPharma Dive on July 7, 2026 3:59 PM

Read Original